Abstract:Toyoaki Hida Lung Cancer Center, Central Japan International Medical Center, Minokamo, Japan Comment on: Oh SY, Lee YW, Lee EJ, et al . Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC. Clin Cancer Res 2023;29:221-32. Keywords: Antibody-drug conjugates (ADCs); EGFR-tyrosine kinase inhibitor resistance (EGFR-TKI resistance); MET gene alterations; biparatopic antibodies (biparatopic Abs); bystander effect Submitted Jan 29, 2024. Accepted for publication Mar 08, 2024. Published online Apr 25, 2024. doi: 10.21037/tlcr-24-100 Antibody-drug conjugates (ADCs) are innovative therapeutic agents made up of a monoclonal antibody (Ab) connecting a cytotoxic agent through a linker. Such drugs exhibit highly specific targeting abilities, could effectively attack targeted cells, and potentially reduce toxicity in contrast with other nontargeted cells. ADCs exert their activity as follows. The first step is tumor penetration, followed by target coupling, then ADC-antigen complex internalization via antigen-dependent endocytosis and endo- or lysosomal trafficking (1). The drug release occurs in the endosomes or lysosomes (1). For individual ADC, the drug-to-antibody ratio (DAR) aims to reflect drug potency and higher cytotoxicity (2). ADCs with higher DAR exhibit more strong in vitro action. However, in vivo experiments displayed faster liver plasma clearance, potentially related to the overall compound volume, making ADCs easily subject to clearance by the liver (3). Cleavable linkers allow for extracellular drug release within the tumor tissue due to the redox tumor microenvironment (TME) with high protease concentrations and low pH (4). Along with passive drug diffusion through the cell membrane after internalization and processing, drug emission in the TME leads to the bystander effect, a cytotoxic action influenced on neighborhood cells irrespective of targeted antigen expression (5). Currently, various ADCs are under evaluation, MET-, HER2-, HER3-, or TROP2-targeting ADCs presenting potential applicability in non-small cell lung cancer (NSCLC). Patritumab deruxtecan is a HER3-targeted ADC with a payload composing of a topoisomerase I inhibitor. As EGFR-tyrosine kinase inhibitor (TKI) treatment can increase cell surface HER3 expression in EGFR-mutant NSCLC, it is interesting to study patritumab deruxtecan in EGFR-mutant NSCLC (6). Osimertinib, a third-generation TKI, is used in first-line therapy for progressed EGFR -mutated NSCLC and in the adjuvant use for stage IB–IIIA operated EGFR -mutated NSCLC. However, osimertinib resistance is an inevitable challenge. The second-line therapy for osimertinib resistance has not yet been established. After disease progression on Osimertinib, patients are often treated with platinum-based chemotherapy with or without an immune checkpoint inhibitor and antiangiogenic therapy (7). Osimertinib resistance patterns, including EGFR-dependent (on-target) and independent (off-target) resistance mechanisms, have thus been studied. Concerning EGFR-independent resistance, tumor growth partly relies on other mechanisms than EGFR signaling, i.e., alternative pathway kinase activation (e.g., MET, HER2, HER3) (8). MET amplification could happen as a resistance mechanism in EGFR -mutant osimertinib-resistant NSCLCs (8). ADCs could provide a potential solution to this obstacle. Telisotuzumab vedotin (Teliso-V) is a MET-targeted ADC made up of ABT-700, an anti-c-Met monoclonal antibody, and monomethyl auristatin E (a powerful microtubule inhibitor) as an anticancer drug. Teliso-V exhibited antitumor effect in solid tumors with MET gene alterations and has thus been studied in clinical studies in patients with acquired EGFR-TKI resistance. In a phase II study [Study of Telisotuzumab Vedotin (ABBV-399) in participants with previously treated c-Met + Non-Small Cell Lung Cancer. https://clinicaltrials.gov/study/NCT03539536], the Teliso-V monotherapy objective response rate (ORR) was 52.2% in the non-squamous EGFR negative group with c-Met high, and 13.3% in patients with EGFR - and c-Met-positive nonsquamous NSCLC (9). Combined Teliso-V and EGFR-TKIs also undergo testing in a phase I/Ib study [A study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 in participants with advanced solid tumors. https://clinicaltrials.gov/study/NCT02099058], involving patients with acquired c-Met overexpression upon first-line osimertinib treatment. In the interim analysis, combined Teliso-V and osimertinib displayed an ORR of 58% in patients previously treated with first-line osimertinib (10). Other newly developed ADCs include ABBV-400 targeting c-MET and topoisomerase with an ongoing phase 1 study [St -Abstract Truncated-

Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth

EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer

Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer

Antibody-drug conjugate development: opening windows for EGFR-mutant EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancers?

Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II

Abstract 2618: BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models

Engineering Of Egfr-Targeted Nanoparticles For Triple Negative Breast Cancer Therapy

Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study

Abstract 2114: Enhancing therapeutic strategies for osimertinib-resistant EGFR-mutant NSCLC: A HER3 dual-payload ADC (dpADC) with topoisomerase I and EGFR tyrosine kinase inhibitor

Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple‑negative breast cancer cell lines

Abstract 1143: Development of a CDK2-selective small molecule inhibitor INCB123667 for the treatment of CCNE1hi breast cancers

EGFR-Targeted Antibody–Drug Conjugate to Different Aminobisphosphonates: Direct and Indirect Antitumor Effects on Colorectal Carcinoma Cells

Abstract 2619: A novel EGFR × HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation

Dual immunostimulatory CD73 antibody-polymeric cytotoxic drug complex for triple negative breast cancer therapy

Abstract 5310: Physiochemical and biological characterization of anti-EGFR based bispecific antibodies in triple negative breast cancer (TNBC) models

Targeting CD137 enhances the efficacy of cetuximab

A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer

Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer

Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability

Abstract 5858: Systematic identification of pathways associated with antibody drug conjugate sensitivity in breast cancer